Basking Biosciences reports promising stroke therapy results
Basking Biosciences, a clinical-stage biopharmaceutical company developing a first-in-class, targeted, reversible thrombolytic therapy for acute ischemic stroke (AIS), has announced the publication of preclinical research in Communications Biology, a Nature Portfolio journal.
The study shows that its lead candidate, BB-031, restores blood flow in a microfluidic model of arterial occlusion using blood samples from AIS patients by selectively inhibiting von Willebrand Factor (vWF), a key mediator of clot initiation, growth and stabilisation. The research was led by scientists at the University of Pittsburgh and The Ohio State University.
The study evaluated how BB-031 reopens vessels and compared its performance with the two approved fibrinolytics, alteplase (tPA) and tenecteplase (TNK). In the model, fully occlusive, platelet-rich clots were formed under arterial flow conditions, allowed to mature for up to six hours, and then treated. Results showed that BB-031 restored blood flow through occluded channels more effectively than both alteplase and tenecteplase, including clots that had matured for three to six hours. BB-031 also worked by preventing vWF from recruiting new platelets to the clot surface, a process that continually reinforces platelet-rich arterial clots and makes them resistant to current fibrinolytics.
“The model allowed us to see what may be happening to arterial clots in prolonged settings, providing a closer analogue to clinical reality. This advance allowed us to better interrogate the potential advantages of a vWF-targeting strategy, complementing our earlier studies,” said Dr Susan M Shea, Assistant Professor in the Trauma and Transfusion Medicine Research Center, Department of Surgery at the University of Pittsburgh and senior author on the study.
Blood samples from AIS patients showed restored blood flow with BB-031 compared with the vehicle. Importantly, clots formed in the model reproduced the clot composition reported in human samples from patients who have undergone endovascular thrombectomy (EVT). These include fibrin, platelets, and vWF, supporting the model as a relevant system for studying arterial thrombosis and treatment.
Results and findings
“These findings show that BB-031 restores blood flow in an occlusive thrombus after a clot has already formed and matured,” said Dr Shahid M Nimjee, Co-Founder, Chief Scientific Officer and stroke clinical lead of Basking Biosciences. “Von Willebrand Factor continually recruits platelets that reinforce arterial clots, thereby engendering resistance to current therapies. By selectively inhibiting vWF, BB-031 stops that reinforcement and allows blood flow to return, even when treatment is administered hours after the occlusion forms. This gives us clear insight into how BB-031 works in human clot formation and strengthens the rationale for our clinical program in acute ischemic stroke.”
Stroke remains one of the leading causes of death and disability worldwide. Fibrinolytics, the pharmacological standard of care since 1996, are limited by a narrow 3- to 4.5-hour treatment window and a serious bleeding risk. Mechanical thrombectomy, adopted globally in 2015, can extend treatment up to 24 hours, but it is available only in specialised centres. Current literature supports limiting it to patients who present with large vessel occlusion stroke. BB-031 offers a different approach. It selectively and reversibly inhibits vWF and can be paired with BB-025, a direct-acting reversal agent designed to rapidly restore normal haemostasis within minutes, if needed, enabling potential urgent surgical intervention in the event of bleeding.
“This publication adds important mechanistic evidence to our program, and it is encouraging to see our approach validated in blood samples from stroke patients,” said Julia C. Owens, Ph.D., chief executive officer of Basking Biosciences. “Findings like these strengthen our conviction as we advance BB-031 through our Phase II RAISE trial and work toward a treatment that could reach many stroke patients who do not currently receive acute treatment.”
The Phase II RAISE trial is a multi-centre, randomised, double-blind, dose-finding study evaluating BB-031 versus placebo in patients with AIS who present within 24 hours of symptom onset. The trial includes two parts. Part A was completed in 2025. Part B will enrol approximately 180 patients. The trial is being conducted at sites across North America and Australia, with additional site activation planned.
